Aditxt

Historical price data

Aditxt is a U.S.-based biotech firm developing technologies to monitor and modulate the immune system through its two core platforms: AditxtScore for immune profiling and Adimune for inducing immune tolerance. Its mission is to translate immune insights into therapies for autoimmune disorders and transplant rejection, with a pipeline primarily in preclinical and early clinical stages. The company faces significant challenges, including extreme stock volatility indicative of financial distress, a pre-revenue status requiring continual capital, and the high-risk nature of developing novel immunology platforms in a crowded competitive landscape.

AditxtScore for immune system profiling and monitoring; Adimune for inducing antigen-specific immune tolerance to treat autoimmune diseases and prevent transplant rejection.

Aditxt competes with well-funded biotechs and large pharma companies in immune tolerance (e.g., Anokion, Sonoma Biotherapeutics) and with major diagnostic firms in immune monitoring. Its limited resources and late entry position it as a significant underdog in both arenas.